Print
16 March 2017
Steve Bremer / europien pharmaceutical review
The UK’s life sciences sector is more than twice as productive as the UK average, according to a report.
The PwC report, commissioned by the Association of the British Pharmaceutical Industry (ABPI) and supported by the Association of the British Healthcare Industry (ABHI), the BioIndustry Association (BIA), and the British In Vitro Diagnostics Association (BIVDA), shows that the average productivity of UK life sciences employees, expressed as gross value added (GVA), is £104,000, compared to the UK average of £49,000.
Other key findings include:
Dr Virginia Acha, ABPI Executive Director – Research, Medical and Innovation, said: “The UK’s productivity problem is well-known, and whether in advanced medicines manufacturing, med-tech or world-leading biopharma R&D, this report emphasises the true value UK Life Sciences has to offer. If we are serious about improving our productivity, increasing public and private investment in science and innovation across the UK will be a fundamental piece of the puzzle.”
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.